Hope S. Rugo reports sponsored research to her institution from Astellas Pharma Inc., AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline, Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, OBI Pharma, Pfizer Inc, Pionyr Immunotherapeutics, Sermonix Pharmaceuticals Inc., Stemline Therapeutics, Taiho Oncology Inc., and Veru Inc. and consultancy/advisory with Puma, NAPO, Mylan, and Daiichi Sankyo. Rachel M. Layman reports advisory/consultancy fees from Novartis, Lilly, Celcuity, Gilead, and Biotheryx and research/grant funding from Pfizer Inc, Novartis, Lilly, GlaxoSmithKline, Zentalis, Puma, Celcuity, Accutar and Arvinas. Tiah Tomlin-Harris serves on a patient advisory board for Pfizer Inc. Adam Brufsky reports advisory/consultancy fees from AstraZeneca, Pfizer Inc, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, and Puma and research support from Agendia and AstraZeneca. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.